ArticleEJNMMI research2025
Elimination of artifacts caused by residual radiopharmaceutical activity in injection site in myocardial perfusion imaging on Discovery NM 530c semiconductor gamma camera.
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac gamma cameras dedicated for myocardial perfusion imaging (MPI) perform studies faster and acquire higher quality images than traditional cameras. However, they are susceptible to some artifacts. We observed a previously unreported artifact, caused by residual radiopharmaceutical activity in injection site in cubital fossa caught in camera field of view. This study aims to assess the impact of these artifacts on image quality and the possibility of their elimination. Study included 50 male patients referred for MPI using Discovery NM 530c gamma camera, in whom radiopharmaceutical activity in injection site was observed in stress or rest study. In such cases, image acquisition was immediately repeated, with the patient and the camera kept in the same position, after covering the injection site with a special lead shield. Obtained images were assessed by two experienced nuclear medicine physicians using a 0-4 point scale in each segment (where 0-normal perfusion, and 4-complete lack of perfusion). Summed stress, rest and difference scores (SSS, SRS and SDS, respectively) were calculated for the entire myocardium and 3 main vascular territories.
resultsSSS, SRS and SDS were most frequently assessed as abnormal in RCA territory. Radiopharmaceutical activity in injection site was observed more frequently in stress studies (84% of cases). Covering injection site with a shield changed the assessment of SSS, SRS or SDS from normal to abnormal and vice versa in almost 20% of studies. The most frequently affected vascular territories were LAD and RCA. Elimination of the artifact changed final diagnosis in almost 1/5 of patients, most often by eliminating previously visible significant stress-induced perfusion defects (patients in whom such change occurred did not report any cardiovascular events in one-year follow-up).
conclusionsArtifacts caused by radiopharmaceutical activity in injection site reduce image quality and can potentially generate or hide perfusion defects. They can be observed mainly in patients examined in prone position, after radiopharmaceutical injection in cubital fossa. These artifacts can be eliminated by a lead shield, which can change the final assessment of MPI study in 20% of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.